Releases Details

Exercise of options and PDMR dealing

May 9, 2023
PDF Version
RNS Number : 6706Y
MaxCyte, Inc.
09 May 2023
 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Exercise of options and PDMR dealing

 

Gaithersburg, Maryland - 9 May 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 3 May 2023, as per a filing lodged with the SEC, Doug Doerfler, Chief Executive Officer, exercised options over 16,149 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 16,149 new shares of Common Stock were issued pursuant to the Company's existing  its block admission facility and were sold by Doug Doerfler at a price range between of $5.00 and $5.03 per Common Stock ("Sale"). The sold shares represent approximately 0.45% of Doug Doerfler's total equity and option holdings in the Company's stock capital, respectively.

 

Following the Exercise and Sale, Doug Doerfler holds 333,197 shares of Common Stock representing 0.3% of the issued stock capital of the Company. Following the Exercise, Doug Doerfler holds a further 3,277,531 options over Common Stock.

 

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Doug Doug Doerfler on 18 November 2022 relating solely to the sale of shares acquired from exercise of an option that expires on 11 November 2024.

 

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

 

+1 415-937-5400

ir@maxcyte.com

 

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500

 

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Doug Doerfler

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Cheif Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

MaxCyte Inc.

b)

 

LEI

 

 

54930053YHXULRFCU991

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Common Stock of $0.01 each



Identification code

US57777K1060



b)

 

Nature of the transaction

 

 

Exercise of Options over common stock

c)

 

Price(s) and volume(s)







Exercise Price(s)

Volume(s)




$0.04

16,149







d)

 

Aggregated information




- Aggregated volume

n/a



- Price

n/a



e)

 

Date of the transaction

 

 

3 May 2023

f)

 

Place of the transaction

 

 

USStock Exchange, Nasdaq

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Doug Doerfler

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Cheif Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

MaxCyte Inc.

b)

 

LEI

 

 

54930053YHXULRFCU991

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Common Stock of $0.01 each



Identification code

US57777K1060



b)

 

Nature of the transaction

 

 

Sale of common stock

c)

 

Price(s) and volume(s)







Exercise Price(s)

Volume(s)




$5.00

1491




$5.005

433




$5.01

869




$5.015

206




$5.02

10,748




$5.025

141




$5.03

2261







d)

 

Aggregated information




- Aggregated volume

16,149



- Price

$5.02



e)

 

Date of the transaction

 

 

3 May  2023

f)

 

Place of the transaction

 

 

US Stock Exchange, Nasdaq

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHAPMRTMTIMBAJ